SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 203.18-1.4%Nov 28 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (21945)6/7/1998 10:07:00 AM
From: Biotech Jim  Read Replies (2) of 32384
 
Having published in Science, the reports or articles are not accepted until the final revisions are made no matter how minor. So, if the small molecule agonist paper is still at the minor revision stage (or was at the time of the annual meeting), it could not be considered as accepted or in press. It would be foolhardy to state that a paper was in press before officially so, and could be quite embarrassing. I am also led to believe that at the time of the Tahoe presentation that the work was not yet submitted. It is usually about two months from acceptance to publication date in Science.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext